LCM
RVNC

Legato Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Legato Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-101,842
Closed -$501K – 631
2024
Q1 		$501K Buy
101,842
+44,190
+77% +$262K 0.06% 439
2023
Q4 		$507K Buy
57,652
+18,903
+49% +$155K 0.07% 414
2023
Q3 		$444K Sell
38,749
-1,017
-3% -$19.6K 0.06% 424
2023
Q2 		$1.01M Buy
39,766
+6,324
+19% +$197K 0.14% 258
2023
Q1 		$1.08M Hold
33,442
– – 0.2% 175
2022
Q4 		$617K Buy
+33,442
New +$765K 0.12% 285

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legato Capital Management's RVNC Position: Q2 2024 in Review

Legato Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 101,842 shares — an estimated $501K sold.

Legato Capital Management first reported a position in RVNC in Q4 2022 and held it in 6 quarters. The position peaked at $1.08M in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Legato Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 101,842 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $501K.
  • Legato Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 6 quarters.
  • Legato Capital Management's Revance Therapeutics, Inc. position peaked at $1.08M in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.